SEC Probes Cassava Sciences
Cassava Sciences has become a hot pick among ambitious investors. In fact, it’s one of the best-performing stocks this year. 👩🔬
The company recently launched into late-stage clinical trials for its Alzheimer’s drug, Simufilam. However, the integrity of Simufilam’s clinical data has become a topic of great controversy in recent months. The company has been accused of “manipulating data and images from data used to support the efficacy“ of its drug. In the Aug. 29 edition of The Daily Rip, we covered a citizen’s petition which aimed to expose data manipulation in Cassava’s clinical trials… even though Cassava claims its drug stopped and reversed progression of the disease.